Join Drs Tania Jain and Brandi Reeves as they discuss primary myelofibrosis and post-ET (essential thrombocythemia) and post-PV (polycythemia vera) myelofibrosis.

FRIDAY, April 4, 2025 (HealthDay News) -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell ...

Dr. Raajit Rampal studies myelofibrosis in the lab and in the clinic. An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a ...

The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that ...

Machine learning model improves transplant risk assessment for patients with myelofibrosis, helping clinicians make informed ...

A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) outperformed standard statistical models in identifying and stratifying transplant ...

They may include: About 10% to 15% of the time, polycythemia vera changes into myelofibrosis. This is called post-polycythemia vera myelofibrosis. Myelofibrosis is a blood cancer where your bone ...

Get Instant Summarized Text (Gist) A phase 3 trial has shown that a combination of JAK inhibitors, pelabresib and ruxolitinib, offers promising results for treatment-naive myelofibrosis patients ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive patients, according to ...

I think the biggest challenge with myelofibrosis is that outside of bone marrow transplantation, which is really only a modality that offers the potential for cure to a segment of our MF patient ...

CALR-mutated myelofibrosis patients often present with more severe disease and require more innovative therapies for better long-term outcomes. Jakafi shows initial benefits, but CALR-mutated patients ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...